Arcturus Therapeutics (ARCT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ARCT Arcturus Therapeutics

Watchlist

16.796
+0.266+1.61%

Trading Dec 26 14:29 ET

454.96MMarket Cap-7.21P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others
Yahoo FinanceDec 24 13:02 ET
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)
TipRanksDec 18 00:50 ET · Ratings
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Dow JonesDec 17 06:27 ET · Ratings
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BusinesswireDec 16 16:01 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight
BenzingaDec 16 08:16 ET
Arcturus Therapeutics Analyst Ratings
BenzingaDec 16 08:14 ET · Ratings

Comments

Laurence john tawil

May 28 10:16

$Arcturus Therapeutics (ARCT.US)$ wtf is happening bout to put this hoe down

Moomoo AI

Mar 9 06:57

Analysts maintain loss per share estimates for next year with no major changes to revenue estimates. However, the company's performance is expected to underperform the wider industry. The steady consensus price target indicates that reduced loss estimates may not positively impact the stock's long-term valuation.

Analysts Have Made A Financial Statement On Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Yearly Report

Moomoo AI

Feb 28 06:46

Despite Arcturus Therapeutics Holdings Inc.'s strong run, its P/S ratio remains low due to a weak revenue outlook. Investors believe the potential for revenue improvement doesn't justify a higher P/S ratio, forming a barrier for the share price.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Iwill TradeScared

Feb 9 12:29

$Arcturus Therapeutics (ARCT.US)$ in game 👀✈️

Moomoo AI

Feb 6 12:49

The recent improvement in total shareholder return could indicate that the business is getting better over time. However, there are 2 warning signs that investors should be aware of. The sentiment around the company seems to be positive lately.

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Delivers Shareholders Incredible 48% CAGR Over 5 Years, Surging 7.2% in the Last Week Alone

Heat List

Overall

No Data